Allurion Technologies, Inc. announced its third-quarter 2025 financial results, reporting a revenue of $2.7 million and a net loss of $11.9 million. The company successfully passed FDA inspections with zero observations and completed its Day-100 meeting, indicating progress towards FDA approval. Additionally, Allurion strengthened its balance sheet by exchanging outstanding debt for convertible preferred equity and securing $5 million in private placement financing.

Allurion reported its first quarter 2025 financial results, showing reduced operating expenses and net operating loss, an improved gross margin, and progress toward FDA approval, while maintaining its full-year revenue guidance.

The company reported Q4 2024 revenue of $5.6 million, down from $8.2 million in the prior year. Gross margin declined to 45% due to lower production volumes and inventory adjustments. Operating expenses were reduced significantly, contributing to a lower net loss compared to previous quarters.

Allurion Technologies reported a revenue of $5.4 million for Q3 2024, which includes a $1.2 million reduction for product recalled from France. The company is updating its full-year 2024 revenue guidance to between $30 million and $35 million and expects growth in procedure volume to be flat year-over-year. A business restructuring plan is expected to reduce operating expenses by 50% in 2025 and achieve profitability by the end of 2025.

Allurion Technologies, Inc. announced its Q2 2024 financial results, highlighted by a sequential revenue increase of $2.4 million from Q1 2024, reaching $11.8 million, and a 12% year-over-year growth in procedure volume. The company's loss from operations decreased by 30% compared to the previous year, and they updated their full-year 2024 revenue guidance to between $40 million and $45 million.

Allurion Technologies, Inc. reported first quarter 2024 revenue of $9.4 million, a 14% increase from the fourth quarter of 2023. The company's cash burn was reduced to $8.4 million, and procedural volume increased by 12% year-over-year. They also launched the Virtual Care Suite (VCS) digital platform in the United States and closed a $48 million convertible senior secured note financing.

Allurion Technologies reported Q4 2023 revenue of $8.2 million, compared to $19.2 million for the same period in 2022. The company's cash and cash equivalents totaled $38 million as of December 31, 2023. They are reiterating the financial guidance it previously published for full year 2024.